Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Aristotle Core Equity Fund Mr. Fitzpatrick | “We sold Boston Scientific on concerns around continued pressure in its two growth engines: the Watchman device and Farapulse. Despite good data in the Champion trial, hesitation around the use of Watchman has resulted in declining growth rates. Changes to the modality of implantation are also pressuring Watchman growth. Farapulse, while a clear leader in pulse field ablation (PFA), is experiencing slower growth rates due to competitive entrants. While we are encouraged by management's actions to address these issues, we believe it will take time to regain investor confidence in the name and restore the premium valuation that Boston Scientific once enjoyed.” | BULL | Q2 2026 Aug 10, 2026 | View Pitch |
TCW Concentrated Large Cap Growth Fund Brandon D. Bond, Bo Fifer, Brian M. McNamara | “Shares of Boston Scientific Corporation (BSX; 1.25%) moved lower after quarterly results and the CHAMPION AF data results. While results modestly beat expectations, two key franchises (U.S. Electrophysiology and Watchman) missed consensus and management lowered 2026 organic sales growth guidance to 10-11%. The durability and growth trajectory for WATCHMAN is a focus for investors, and although CHAMPION-AF data released at the end of March hit all endpoints, they failed to act as a positive catalyst for BSX shares. Though we recognize the timing and magnitude of WATCHMAN contribution may not be resolved in the near-term, we believe current valuation may have overly discounted the company's long-term earnings growth profile. Shares remain under review.” | BULL | Q2 2026 Jul 29, 2026 | View Pitch |
Parnassus Growth Equity Fund Andrew Choi & Shivani Vohra | “Boston Scientific detracted after growth slowed in two of its key businesses, its electrophysiology franchise and Watchman heart implant, due to growing competition and mixed clinical trial results. We exited the stock during the quarter. We exited Boston Scientific as the competitive environment evolved more quickly than anticipated. Growth in key franchises, Farapulse and Watchman, slowed due to competitive pressures and mixed clinical trial outcomes. While market share may stabilize over time, reduced visibility into a near-term reacceleration led us to reallocate capital toward higher-conviction opportunities.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Parnassus Core Equity Fund Benjamin Allen, Todd Ahlsten, Andrew Choi | “Boston Scientific detracted after growth slowed in two of its key businesses—its electrophysiology franchise and Watchman heart implant for reducing stroke risk—amid growing competition and mixed clinical trial results. We exited the stock during the quarter. We exited Boston Scientific as the competitive environment evolved more quickly than anticipated. Growth in key franchises—particularly Farapulse and Watchman—slowed due to earlier-than-expected competitive pressures and mixed clinical trial outcomes. While market share may stabilize over time, reduced visibility into a near-term reacceleration led us to reallocate capital toward higher-conviction opportunities with more compelling risk/reward profiles.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Edgewood Management Alan Breed | “A highly innovative pipeline in cardiology and other medtech spaces continues to fuel double-digit revenue growth and operating leverage. Recent stock declines over competitive fears were unwarranted and contradicted by the company's solid mid-term financial and margin expansion targets.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Edgewood Management Alan Breed | “Global medical technology manufacturer of devices used in interventional procedures across cardiology, endoscopy, neuromodulation, and urology markets. Thesis: Innovative portfolio in high growth categories drives durable double digit organic revenue growth. Disciplined expense management and smart capital deployment lead to mid-teens EPS growth. Strong pipeline across multiple disease categories offers LT optionality. Q2 Results: Revenue +23% (+17% organic) and EPS +21%. Raised FY25 guidance on strength in WATCHMAN (AFib implant device), EP, and endoscopy. What Happened: Shares advanced +4% post-earnings on accelerating momentum in key segments. Leading into 9/30 investor day, shares declined ~10% on growth and competition concerns. Edgewood's View: We believe the selloff was unwarranted and took advantage to continue building our position. Resulting Action: Edgewood added 100bps during the quarter; 9/30 investor day confirmed double digit + organic revenue growth and margin expansion over the next 3 years. BSD Analysis: Boston Scientific is entering 2026 with exceptional momentum, projecting 10% to 11% organic revenue growth and a targeted adjusted EPS of up to $3.49. The company's cardiovascular segment, a $50 billion addressable market, remains its primary engine of growth, with electrophysiology sales expected to outpace the market at 15% through its "Watchman" and "Acurate" franchises. Despite a 150-basis-point headwind from recent product discontinuations, management anticipates margin expansion of up to 75 basis points as higher-margin innovations like the OPAL mapping system gain traction globally. Clinical data expected in the second half of 2026 for the "Simplify" trial could serve as a major catalyst for its structural heart business. With shares consistently outperforming the broader medtech industry, Boston Scientific offers a high-conviction combination of organic growth and operational discipline.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Harbor Capital Appreciation Fund Kathleen A. McCarragher, Blair A. Boyer, Natasha Kuhlkin | “We initiated a position in Boston Scientific, a leading medical device company specializing in stroke prevention for patients with atrial fibrillation. The recent U.S. Food and Drug Administration's approval of a breakthrough heart rhythm device, along with continued momentum in stroke reduction products, position Boston Scientific for potential accelerated growth. BSD Analysis: Boston Scientific is a diversified medical device leader with strong momentum across cardiovascular, neuromodulation, and minimally invasive therapies. Its pipeline productivity has been impressive, with new products consistently gaining share and driving above-market growth. The company's exposure to high-acuity, non-elective procedures gives it resilience even in macro slowdowns. Margin expansion continues as mix shifts toward higher-value cardiology and electrophysiology products. M&A remains a strategic weapon, and Boston Sci has a strong record of integrating tuck-ins. Regulatory hurdles exist, but execution has been excellent. It's a high-quality medtech compounder with sustained innovation velocity.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
